Outlook Therapeutics (OTLK) Other Non-Current Assets (2015 - 2026)
Outlook Therapeutics (OTLK) reported Other Non-Current Assets of $320290.0 for Q1 2026, down 18.67% year-over-year from $393831.0 in Q1 2025, and down 7.46% quarter-over-quarter from $346111.0 in Q4 2025.
Outlook Therapeutics (OTLK) Other Non-Current Assets (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Other Non-Current Assets data on file, last reported at $320290.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $320290.0, down 18.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $320290.0 (down 18.67% YoY), and the FY2025 annual result was $417523.0, down 4.95% from the prior year.
- Other Non-Current Assets eased to $320290.0 in Q1 2026 per OTLK's latest filing, from $346111.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $589365.0 in Q2 2023 and troughed at $113850.0 in Q1 2023.
- A 5-year average of $351728.0 and a median of $415974.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets slipped 27.78% in 2022, then surged 319.91% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $126442.0 in 2022, then jumped by 283.04% to $484320.0 in 2023, then declined by 14.11% to $415974.0 in 2024, then dropped by 16.8% to $346111.0 in 2025, then declined by 7.46% to $320290.0 in 2026.
- Business Quant data shows OTLK's Other Non-Current Assets at $320290.0 in Q1 2026, $346111.0 in Q4 2025, and $417523.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | 320,290.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 320,290.00 |
| Dec 31, 2025 | 346,111.00 |
| Sep 30, 2025 | 417,523.00 |
| Jun 30, 2025 | 464,388.00 |
| Mar 31, 2025 | 393,831.00 |
| Dec 31, 2024 | 415,974.00 |
| Sep 30, 2024 | 439,283.00 |
| Jun 30, 2024 | 479,229.00 |
| Mar 31, 2024 | 473,241.00 |
| Dec 31, 2023 | 484,320.00 |
| Sep 30, 2023 | 501,299.00 |
| Jun 30, 2023 | 589,365.00 |
| Mar 31, 2023 | 113,850.00 |
| Dec 31, 2022 | 126,442.00 |
| Sep 30, 2022 | 132,015.00 |
| Jun 30, 2022 | 140,356.00 |
| Mar 31, 2022 | 141,859.00 |
| Dec 31, 2021 | 156,702.00 |
| Sep 30, 2021 | 174,590.00 |
| Jun 30, 2021 | 194,355.00 |